(Q84047213)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

0 references

Lisa E Hines

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

John E Murphy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Amy J Grizzle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Daniel C Malone

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

941-946

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Drug-drug interactions among elderly patients hospitalized for drug toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Oral erythromycin and the risk of sudden death from cardiac causes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Potential Drug???Drug Interactions in the Outpatient Setting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Assessment of potential drug-drug interactions with a prescription claims database

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

The "meaningful use" regulation for electronic health records

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Identification of drug interactions in hospitals--computerized screening vs. bedside recording

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Pharmacist recognition of potential drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Concordance of severity ratings provided in four drug interaction compendia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Comparative assessment of four drug interaction compendia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Mixed results in the safety performance of computerized physician order entry

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Evaluation of drug interaction software to identify alerts for transplant medications.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Black box warning contraindicated comedications: concordance among three major drug interaction screening programs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Predicting the clinical relevance of drug interactions from pre-approval studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Improvement in the handling of drug-drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Systematic overview of warfarin and its drug and food interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Drug interactions in primary care: impact of a new algorithm on risk determination

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Clinical decision support and electronic prescribing systems: a time for responsible thought and action

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Improving acceptance of computerized prescribing alerts in ambulatory care.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Using commercial knowledge bases for clinical decision support: opportunities, hurdles, and recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Implementing a commercial rule base as a medication order safety net

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Grand challenges in clinical decision support

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Clinical decision support in electronic prescribing: recommendations and an action plan: report of the joint clinical decision support workgroup

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Overrides of medication alerts in ambulatory care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Community pharmacists' responses to drug-drug interaction alerts

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Clinicians' assessments of electronic medication safety alerts in ambulatory care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Physicians' decisions to override computerized drug alerts in primary care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Community pharmacy managers' perception of computerized drug-drug interaction alerts

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Practitioners' views on computerized drug-drug interaction alerts in the VA system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Unintended consequences of reducing QT-alert overload in a computerized physician order entry system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

Turning off frequently overridden drug alerts: limited opportunities for doing it safely

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100440

31 March 2020

Identifiers

DOI

10.2146/AJHP100440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21546646%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference